133 related articles for article (PubMed ID: 19491003)
1. Angiotensin II receptor blockers in pregnancy: a report of five cases.
Gersak K; Cvijic M; Cerar LK
Reprod Toxicol; 2009 Jul; 28(1):109-12. PubMed ID: 19491003
[TBL] [Abstract][Full Text] [Related]
2. [Transient renal failure in a newborn due angiotensin receptor II antagonist use during pregnancy: report of a case].
Hasbún H J; Valdés R E; San Martín O A; Catalán M J; Salinas Q S; Parra C M
Rev Med Chil; 2008 May; 136(5):624-30. PubMed ID: 18769811
[TBL] [Abstract][Full Text] [Related]
3. Fetal toxic effects of angiotensin II receptor antagonists: case report and follow-up after birth.
Bos-Thompson MA; Hillaire-Buys D; Muller F; Dechaud H; Mazurier E; Boulot P; Morin D
Ann Pharmacother; 2005 Jan; 39(1):157-61. PubMed ID: 15590878
[TBL] [Abstract][Full Text] [Related]
4. Fetal toxic effects and angiotensin-II-receptor antagonists.
Martinovic J; Benachi A; Laurent N; Daikha-Dahmane F; Gubler MC
Lancet; 2001 Jul; 358(9277):241-2. PubMed ID: 11480433
[No Abstract] [Full Text] [Related]
5. Oligohydramnios and pulmonary hypoplasia: a case in which involvement of an angiotensin II receptor antagonist was suspected.
Kato K; Okuda M; Ishikawa H; Takahashi T; Hirahara F
J Obstet Gynaecol Res; 2008 Apr; 34(2):242-6. PubMed ID: 18412789
[TBL] [Abstract][Full Text] [Related]
6. [Microalbuminuria in patients with hypertension and cardiovascular comorbidity, REAL observational study of treatment with Irbesartan/HCTZ].
Tschöpe C; Tschöpe R; Unger T
MMW Fortschr Med; 2006 Jun; 148(25):48. PubMed ID: 16859162
[No Abstract] [Full Text] [Related]
7. Pregnancy outcome after in utero exposure to angiotensin converting enzyme inhibitors or angiotensin receptor blockers.
Diav-Citrin O; Shechtman S; Halberstadt Y; Finkel-Pekarsky V; Wajnberg R; Arnon J; Di Gianantonio E; Clementi M; Ornoy A
Reprod Toxicol; 2011 May; 31(4):540-5. PubMed ID: 21338666
[TBL] [Abstract][Full Text] [Related]
8. [Fetal toxicity of angiotensin-II-receptor inhibitors. Case report].
Roger N; Popovic I; Madelenat P; Mahieu-Caputo D
Gynecol Obstet Fertil; 2007 Jun; 35(6):556-60. PubMed ID: 17544313
[TBL] [Abstract][Full Text] [Related]
9. Increased renal echogenicity in a preterm neonate. Kidneys with tubular dysplasia due to exposure to candesartan during pregnancy.
Bald M; Holder M; Zieger M; Vochem M; Leichter HE
Pediatr Nephrol; 2005 Nov; 20(11):1664-5, 1666-8. PubMed ID: 16082550
[No Abstract] [Full Text] [Related]
10. Warnings against candesartan in pregnancy are not implemented in physicians' practice.
Borthen C; Oglaend B; Eggebøe T; Ellingsen CL; Schjøtt J
Eur J Obstet Gynecol Reprod Biol; 2009 Oct; 146(2):235. PubMed ID: 19615811
[No Abstract] [Full Text] [Related]
11. Pregnancy outcome after first trimester use of angiotensin AT1 receptor blockers: an observational cohort study.
Hoeltzenbein M; Tissen-Diabaté T; Fietz AK; Zinke S; Kayser A; Meister R; Weber-Schoendorfer C; Schaefer C
Clin Res Cardiol; 2018 Aug; 107(8):679-687. PubMed ID: 29574489
[TBL] [Abstract][Full Text] [Related]
12. Course and outcome of pregnancy after maternal exposure to angiotensin-II-receptor blockers--case report and review of the literature.
Enzensberger C; Eskef K; Schwarze A; Faas D; Axt-Fliedner R
Ultraschall Med; 2012 Oct; 33(5):493-6. PubMed ID: 21630188
[No Abstract] [Full Text] [Related]
13. Angiotensin-II-receptor inhibitors in pregnancy.
Hinsberger A; Wingen AM; Hoyer PF
Lancet; 2001 May; 357(9268):1620. PubMed ID: 11386315
[No Abstract] [Full Text] [Related]
14. In utero losartan withdrawal and subsequent development of fetal inferior vena cava thrombosis.
Bakkum JN; Brost BC; Johansen KL; Johnston BW; Watson WJ
Obstet Gynecol; 2006 Sep; 108(3 Pt 2):739-40. PubMed ID: 17018485
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and tolerability of fimasartan, a new angiotensin receptor blocker, compared with losartan (50/100 mg): a 12-week, phase III, multicenter, prospective, randomized, double-blind, parallel-group, dose escalation clinical trial with an optional 12-week extension phase in adult Korean patients with mild-to-moderate hypertension.
Lee SE; Kim YJ; Lee HY; Yang HM; Park CG; Kim JJ; Kim SK; Rhee MY; Oh BH;
Clin Ther; 2012 Mar; 34(3):552-568, 568.e1-9. PubMed ID: 22381711
[TBL] [Abstract][Full Text] [Related]
16. Comparative vascular and renal tubular effects of angiotensin II receptor blockers combined with a thiazide diuretic in humans.
Coltamai L; Maillard M; Simon A; Vogt B; Burnier M
J Hypertens; 2010 Mar; 28(3):520-6. PubMed ID: 20104189
[TBL] [Abstract][Full Text] [Related]
17. Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in women of childbearing age: risks versus benefits.
Pucci M; Sarween N; Knox E; Lipkin G; Martin U
Expert Rev Clin Pharmacol; 2015 Mar; 8(2):221-31. PubMed ID: 25612630
[TBL] [Abstract][Full Text] [Related]
18. Gestational therapy with an angiotensin II receptor antagonist and transient renal failure in a premature infant.
Bass JK; Faix RG
Am J Perinatol; 2006 Jul; 23(5):313-7. PubMed ID: 16799914
[TBL] [Abstract][Full Text] [Related]
19. Human fetal malformations associated with the use of an angiotensin II receptor antagonist: case report.
Korkes HA; de Oliveira LG; Berlinck L; Goes FS; Borges AF; Kirsztajn GM; Sass N
J Bras Nefrol; 2014; 36(3):410-3. PubMed ID: 25317627
[TBL] [Abstract][Full Text] [Related]
20. Teratogenicity with angiotensin II receptor antagonists in pregnancy.
Boix E; Zapater P; Picó A; Moreno O
J Endocrinol Invest; 2005 Dec; 28(11):1029-31. PubMed ID: 16483184
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
